BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021

Rhea-AI Summary

BeiGene (NASDAQ: BGNE) is set to present multiple studies at the AACR Annual Meeting 2021, including three oral presentations on the anti-PD-1 antibody tislelizumab and its combination with the investigational sitravatinib for treating various cancers. Key presentations include:

• RATIONALE 303: Phase 3 study results of tislelizumab in NSCLC, presented on April 12.
• Sitravatinib plus tislelizumab: Safety and preliminary activity in ovarian cancer, on April 11.
• Melanoma study: Safety and tolerability results, also on April 11.

These findings may impact the company's future drug development and market strategies.

Positive

• Multiple presentations showcase promising clinical data on tislelizumab and sitravatinib.
• Potential market expansion with novel combination therapies for advanced cancers.

Negative

• None.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, including three oral presentations to highlight clinical data on anti-PD-1 antibody tislelizumab and on investigational spectrum-selective kinase inhibitor sitravatinib in combination with tislelizumab, and one poster presentation of preclinical data on its investigational anti-TIGIT antibody ociperlimab (BGB-A1217). The AACR Annual Meeting will take place in a virtual format on April 10-15 and May 17-21, 2021.

Oral Presentations:
Title:		Results from RATIONALE 303: A global Phase 3 study of tislelizumab versus docetaxel as second or third-line therapy for patients with locally advanced or metastatic NSCLC
Presentation #:		CT039
Session Title:		Disease-Oriented Innovative Clinical Research and Trials
Date and Time:		Monday, April 12, 2021 at 1:30 – 3:15 p.m. ET
Presenter:		Professor Caicun Zhou, Shanghai Pulmonary Hospital, China
Title:		Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with advanced platinum-resistant ovarian cancer (PROC)
Presentation #:		CT013
Session Title:		Targeted Therapy and Ovarian Cancer Trials
Date and Time:		Sunday, April 11, 2021 at 2:00 – 3:45 p.m. ET
Presenter:		Jeffrey Goh, MBBS, FRACP, Icon Cancer Centre, Australia
Title:		Safety/tolerability and preliminary antitumor activity of sitravatinib plus tislelizumab in patients with PD-(L)1 refractory/resistant unresectable or metastatic melanoma from a phase 1b study
Presentation #:		CT035
Session Title:		Clinical Trials with Novel Immuno-Oncology Strategies
Date and Time:		Sunday, April 11, 2021 at 4:00 – 5:45 p.m. ET
Presenter:		Professor Chuanliang Cui, Beijing Cancer Hospital, China

About BeiGene

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 5,400+ employees around the world are committed to expediting the development of a diverse pipeline of novel therapeutics. We currently market two internally discovered oncology medicines: BTK inhibitor BRUKINSA^® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products in China licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma; and have entered a collaboration with Novartis Pharma AG for Novartis to develop and commercialize tislelizumab in North America, Europe, and Japan. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005917/en/

FAQ

What are the key presentations BeiGene will make at the AACR Annual Meeting 2021?

BeiGene will present data on tislelizumab and sitravatinib in three oral presentations, focusing on NSCLC, ovarian cancer, and melanoma.

When is BeiGene's presentation on the RATIONALE 303 study?

The RATIONALE 303 study results will be presented on April 12, 2021.

What is the significance of the data shared on sitravatinib plus tislelizumab?

The data focuses on the safety and preliminary anti-tumor activity of this combination in patients with advanced cancers, indicating potential new treatment options.

How might the results impact BeiGene's future?

The results could influence the development and commercialization strategies for BeiGene's oncology pipeline, potentially enhancing market opportunities.